BRPI0919796A2 - formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável - Google Patents
formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitávelInfo
- Publication number
- BRPI0919796A2 BRPI0919796A2 BRPI0919796A BRPI0919796A BRPI0919796A2 BR PI0919796 A2 BRPI0919796 A2 BR PI0919796A2 BR PI0919796 A BRPI0919796 A BR PI0919796A BR PI0919796 A BRPI0919796 A BR PI0919796A BR PI0919796 A2 BRPI0919796 A2 BR PI0919796A2
- Authority
- BR
- Brazil
- Prior art keywords
- free liquid
- sugar free
- pharmaceutically acceptable
- pharmaceutical formulation
- excipient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08425654 | 2008-10-09 | ||
| PCT/EP2009/062501 WO2010040652A1 (en) | 2008-10-09 | 2009-09-28 | Liquid pharmaceutical formulation containing paracetamol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0919796A2 true BRPI0919796A2 (pt) | 2015-12-15 |
Family
ID=40282272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0919796A BRPI0919796A2 (pt) | 2008-10-09 | 2009-09-28 | formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20120115958A1 (enExample) |
| EP (1) | EP2349207B1 (enExample) |
| JP (1) | JP2012505172A (enExample) |
| KR (1) | KR20110067103A (enExample) |
| CN (1) | CN102159184B (enExample) |
| AR (1) | AR073793A1 (enExample) |
| AU (1) | AU2009301296A1 (enExample) |
| BR (1) | BRPI0919796A2 (enExample) |
| CA (1) | CA2737391A1 (enExample) |
| EA (1) | EA018401B1 (enExample) |
| GE (1) | GEP20135723B (enExample) |
| MX (1) | MX2011003695A (enExample) |
| UA (1) | UA103906C2 (enExample) |
| WO (1) | WO2010040652A1 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011282252B2 (en) * | 2010-07-21 | 2014-08-21 | Alcon Research, Ltd. | Pharmaceutical composition with enhanced solubility characteristics |
| US9549909B2 (en) | 2013-05-03 | 2017-01-24 | The Katholieke Universiteit Leuven | Method for the treatment of dravet syndrome |
| MA40599A1 (fr) * | 2014-12-20 | 2017-11-30 | Troikaa Pharmaceuticals Ltd | Formulations injectables de paracétamol |
| CA3007673A1 (en) | 2015-12-22 | 2017-06-29 | Zogenix International Limited | Metabolism resistant fenfluramine analogs and methods of using the same |
| PL4293009T3 (pl) | 2015-12-22 | 2025-10-06 | Zogenix International Limited | Kompozycje fenfluraminy i sposoby ich wytwarzania |
| IL290727B2 (en) | 2016-08-24 | 2023-12-01 | Zogenix International Ltd | Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same |
| TWI620577B (zh) * | 2016-11-23 | 2018-04-11 | 乙醯胺酚及曲馬多共溶複方止痛口服液 | |
| US10682317B2 (en) * | 2017-09-26 | 2020-06-16 | Zogenix International Limited | Ketogenic diet compatible fenfluramine formulation |
| GR1009462B (el) * | 2017-10-05 | 2019-02-15 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Ποσιμο φαρμακευτικο διαλυμα με συγκαλυμμενη γευση |
| CN110115708A (zh) * | 2018-02-07 | 2019-08-13 | 保瑞药业股份有限公司 | 乙酰胺酚及曲马多共溶复方止痛口服液 |
| GR1009630B (el) | 2018-03-14 | 2019-10-25 | Laboserve Φαρμακευτικη Βιομηχανια Α.Ε. | Ποσιμα διαλυματα που περιλαμβανουν τραμαδολη και ακεταμινοφαινη |
| US11571397B2 (en) | 2018-05-11 | 2023-02-07 | Zogenix International Limited | Compositions and methods for treating seizure-induced sudden death |
| EP3806835A1 (en) | 2018-06-14 | 2021-04-21 | Zogenix International Limited | Compositions and methods for treating respiratory depression with fenfluramine |
| CA3117868A1 (en) | 2018-11-19 | 2020-05-28 | Zogenix International Limited | Methods of treating rett syndrome using fenfluramine |
| NL2024161B1 (en) * | 2019-11-05 | 2021-07-20 | Mperium B V | Pharmaceutical liquid composition, kit of parts comprising the pharmaceutical liquid composition, and method for preparing the pharmaceutical liquid composition |
| US11612574B2 (en) | 2020-07-17 | 2023-03-28 | Zogenix International Limited | Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) |
| AU2023277704A1 (en) * | 2022-05-25 | 2024-12-05 | Boehringer Ingelheim Vetmedica Gmbh | Aqueous pharmaceutical compositions comprising sglt-2 inhibitors |
| PL4368171T3 (pl) | 2022-11-08 | 2025-09-22 | Laboratorios Ern S.A. | Roztwór doustny paracetamolu |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101572B2 (en) * | 2001-12-07 | 2006-09-05 | Unilab Pharmatech, Ltd. | Taste masked aqueous liquid pharmaceutical composition |
| US8128958B2 (en) * | 2003-11-10 | 2012-03-06 | Astellas Pharma Inc. | Sustained release pharmaceutical composition |
| US20080139528A1 (en) * | 2003-12-10 | 2008-06-12 | Pujara Chetan P | Cefdinir oral suspension |
| US20060093629A1 (en) * | 2004-10-29 | 2006-05-04 | Buehler Gail K | Dye-free pharmaceutical suspensions and related methods |
| WO2007070504A2 (en) * | 2005-12-13 | 2007-06-21 | Morton Grove Pharmaceuticals, Inc. | Stable and palatable oral liquid sumatriptan compositions |
| US20080085892A1 (en) * | 2006-08-31 | 2008-04-10 | Sangeetha Kandeepan | Liquid dosage form of acetaminophen |
-
2009
- 2009-09-28 BR BRPI0919796A patent/BRPI0919796A2/pt not_active IP Right Cessation
- 2009-09-28 MX MX2011003695A patent/MX2011003695A/es active IP Right Grant
- 2009-09-28 WO PCT/EP2009/062501 patent/WO2010040652A1/en not_active Ceased
- 2009-09-28 JP JP2011530451A patent/JP2012505172A/ja active Pending
- 2009-09-28 CA CA2737391A patent/CA2737391A1/en not_active Abandoned
- 2009-09-28 EA EA201170543A patent/EA018401B1/ru not_active IP Right Cessation
- 2009-09-28 CN CN2009801367138A patent/CN102159184B/zh not_active Expired - Fee Related
- 2009-09-28 US US13/062,536 patent/US20120115958A1/en not_active Abandoned
- 2009-09-28 KR KR1020117006413A patent/KR20110067103A/ko not_active Ceased
- 2009-09-28 EP EP09818803.0A patent/EP2349207B1/en active Active
- 2009-09-28 UA UAA201102549A patent/UA103906C2/ru unknown
- 2009-09-28 AU AU2009301296A patent/AU2009301296A1/en not_active Abandoned
- 2009-09-28 GE GEAP200912218A patent/GEP20135723B/en unknown
- 2009-10-08 AR ARP090103867A patent/AR073793A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA201170543A1 (ru) | 2011-10-31 |
| EP2349207B1 (en) | 2015-05-13 |
| US20120115958A1 (en) | 2012-05-10 |
| AR073793A1 (es) | 2010-12-01 |
| GEP20135723B (en) | 2013-01-10 |
| CA2737391A1 (en) | 2010-04-15 |
| JP2012505172A (ja) | 2012-03-01 |
| EP2349207A1 (en) | 2011-08-03 |
| CN102159184B (zh) | 2013-09-04 |
| WO2010040652A1 (en) | 2010-04-15 |
| CN102159184A (zh) | 2011-08-17 |
| AU2009301296A1 (en) | 2010-04-15 |
| MX2011003695A (es) | 2011-08-17 |
| UA103906C2 (ru) | 2013-12-10 |
| EA018401B1 (ru) | 2013-07-30 |
| KR20110067103A (ko) | 2011-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0919796A2 (pt) | formulação farmacêutica líquida livre de açúcar, e, excipiente líquido livre de açucar farmaceuticamente aceitável | |
| IL275854A (en) | Pharmaceutical composition and its administration | |
| BRPI1009324A2 (pt) | compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos | |
| BRPI0821474A2 (pt) | formulação farmacêutica líquida estável | |
| DK2381988T3 (da) | Medikamentadministrationsanordning | |
| EP2398459A4 (en) | TRANSDERMAL RELEASE OF DICLOFENAC, CARBAMAZEPINE AND BENZYDAMINE | |
| GB2450753B (en) | New Pharmaceutical formulation | |
| BRPI0921507A2 (pt) | composição, método de preparação de um excipiente, comprimido farmacêutico e método de preparação do mesmo | |
| DK2346495T4 (da) | Farmaceutisk formulering 514 | |
| BRPI0807544A2 (pt) | Sólido farmacêutico e dose de vacina | |
| DK1983964T3 (da) | Anordning til indgivelse af lægemiddel | |
| DK2274032T3 (da) | Anordning til medicinindgivelse | |
| SMT201400069B (it) | Formulazione farmaceutica | |
| ZA201101948B (en) | Pharmaceutical dosage forms comprising poly(e-caprolactone) | |
| DK2073795T3 (da) | Misbrugssikret lægemiddelformulation | |
| BRPI0820381A2 (pt) | Formulações farmacêuticas | |
| EP2246052A4 (en) | RASCH IN THE MOUTH DAMAGING TABLET WITH IMIDAFENACIN | |
| BRPI0921654A2 (pt) | formulação farmacêutica | |
| BRPI0807078A2 (pt) | Composto, e, formulação farmacêutica | |
| BR112012003800A2 (pt) | composição, peptídeo, e formulação farmacêutica. | |
| BRPI1009392A2 (pt) | "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica." | |
| DK2391351T3 (da) | Farmaceutisk sammensætning omfattende 2-oxo-1-pyrrolidinderivater | |
| GB0709541D0 (en) | Pharmaceutical excipient | |
| BRPI0907228A2 (pt) | Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos | |
| BRPI0910570A2 (pt) | uso de bioconjugados, e, formulações farmacêuticas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |